Menu
Back to Journals » Drug Design, Development and Therapy » Volume 11
Original Research
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 10,384 | Dovepress* | 9,499+ | 941 | 10,440 | |
| PubMed Central* | 885 | 292 | 1,177 | ||
| Totals | 10,384 | 1,233 | 11,617 | ||
| *Since 7 November 2017 | |||||
View citations on PubMed Central and Google Scholar